首页|中药单体干预增生性玻璃体视网膜病变的研究进展

中药单体干预增生性玻璃体视网膜病变的研究进展

扫码查看
增生性玻璃体视网膜病变(PVR)是导致孔源性视网膜脱离手术失败和复发的主要原因.目前临床治疗PVR多以手术为主,但存在一定不足,因此,需要寻找新的药物疗法.中药单体兼有中药与化学药的双重优势,我国传统中药与中药单体在PVR治疗尤其是视网膜保护方面具有独特优势,逐渐成为了研究热点.本文对近年来中药单体治疗PVR的文献进行综述,发现姜黄素、藏红花素、槲皮素等中药单体可通过降低血小板源性生长因子、转化生长因子、表皮生长因子等因子的表达,抑制上皮细胞—间充质转化的生物学过程,防止PVR的发生.这些中药单体的发现对后续新药的研发可提供新的选择,为PVR的治疗提供更多元化的方法.
Research Progress on the Intervention of Chinese Medicine Monomers in Proliferative Vitreoretinopathy
Proliferative vitreoretinopathy(PVR)is a major cause of surgical failure and recur-rence in rhegmatogenous retinal detachment.Current clinical treatments for PVR mainly rely on surgery,but they have certain limitations.Therefore,it is necessary to explore new medicine thera-pies.Chinese medicine monomers,with the dual advantages of Chinese medicine and chemical medicines,have become a research focus,particularly in the protection of the retina in PVR treat-ment.This article reviews the literature on the treatment of PVR with Chinese medicine monomers in recent years.It was found that monomers such as curcumin,saffron,and quercetin can lower the expression of platelet-derived growth factor,transforming growth factor,epidermal growth factor,and other factors.They inhibit the biological process of epithelial-mesenchymal transition,prevent-ing the occurrence of PVR.The discovery of these Chinese medicine monomers provides new op-tions for the development of novel medicines and offers a more diversified approach to the treat-ment of PVR.

proliferative vitreoretinopathyChinese medicine monomersretinal pigment epi-thelial cellspathological mechanism

赵敏瑶、虞玥、宋正宇

展开 >

上海中医药大学附属曙光医院,上海 201203

增生性玻璃体视网膜病变 中药单体 视网膜色素上皮细胞 病理机制

上海市自然科学基金上海中医药大学附属曙光医院四明青年基金

18ZR1440200SGKJ-202111

2024

中国中医眼科杂志
中国中医科学院

中国中医眼科杂志

CSTPCD
影响因子:0.476
ISSN:1002-4379
年,卷(期):2024.34(1)
  • 1
  • 6